FTC sues to block GTCR’s ‘unlawful acquisition’ of Surmodics
GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly concerns.
FTC sues to block merger of device coatings companies
The Federal Trade Commission has filed a lawsuit to block private equity firm GTCR BC Holdings from acquiring Surmodics, a medical technology company, arguing the deal would reduce competition for critical device coatings.
FTC sues to block medical device coatings deal
The Federal Trade Commission under President Trump is making its first move to challenge private equity in health care, by suing to block the $627 million acquisition of a maker of specialized coatings for catheters and other medical devices.
FTC sues to block Surmodics acquisition by private equity over device coating competition
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% of the hydrophilic coating market.
Surmodics says it will defend proposed acquisition by GTCR against FTC lawsuit
The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device coatings, is anticompetitive.” The acquisition of Surmodics by GTCR for $627 million was announced in May.
FTC Sues GTCR, Surmodics Over Medical Device Coatings Deal (1)
The Federal Trade Commission sued Thursday to block private equity firm GTCR BC Holdings’ acquisition of Surmodics Inc., alleging the deal will lead to further concentration in the market for coatings used by medical device manufacturers.
FTC sues to block GTCR’s $627M Surmodics acquisition
The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.
FTC Fights to Block Merger Threatening Healthcare Innovation and Patient-Critical Devices
The Federal Trade Commission (FTC) has filed a lawsuit seeking to block GTCR BC Holdings, LLC’s (GTCR) proposed acquisition of Surmodics, Inc., citing significant antitrust concerns. The
Crain's Chicago Business4d
FTC targets GTCR in agency's first merger challenge under new Trump term
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
Zacks Investment Research on MSN4d
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
Surmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...
PE Hub1d
Archimed plans to make BioVendor a European player in diagnostics
Archimed has bought BioVendor, with plans to build and internationalize the Czech diagnostics company. Archimed sees ...
Surmodics upgraded to Buy from Hold at Lake Street
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
Why Surmodics Stock Is Falling On Friday
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.